/CYDY
CYDY Stock - CytoDyn Inc.
Healthcare|BiotechnologyOTC
$0.28-1.71%
$0.00 (-1.71%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.31
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CYDY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.28 – $0.28
TARGET (TP)$0.32
STOP LOSS$0.26
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.33
52W High$0.49
52W Low$0.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $-5,916,000 | N/A | N/A | $266,000 | N/A |
| Gross Profit | $-18,000 | $-29,000 | $-175,000 | $213,000 | $-1,797,000 |
| Gross Margin | 0.3% | N/A | N/A | 80.1% | N/A |
| Operating Income | $11.32M | $-18,058,000 | $-40,576,000 | $-145,404,000 | $-104,596,000 |
| Net Income | $3.75M | $-49,841,000 | $-79,824,000 | $-210,820,000 | $-174,018,000 |
| Net Margin | -63.3% | N/A | N/A | -79255.6% | N/A |
| EPS | $0.00 | $-0.05 | $-0.10 | $-0.43 | $-0.30 |
Company Overview
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CYDYBeat Rate
0%
Last 5 quarters
Avg Surprise
-82.6%
EPS vs Estimate
Beats / Misses
0/4
1 met exactly
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q1 2026 | Jan 14, 2026 | — | — | — | — |
Q4 2025 | Oct 10, 2025 | — | $-0.00 | — | — |
Q3 2025 | Jul 25, 2025 | — | $-0.01 | — | — |
Q2 2025 | Apr 14, 2025 | — | $-0.00 | — | — |
Q1 2025 | Jan 14, 2025 | — | $-0.00 | — | — |
Q4 2024 | Oct 15, 2024 | — | $0.02 | — | — |
Q3 2024 | Aug 15, 2024 | — | $-0.02 | — | — |
Q2 2024 | Apr 15, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 16, 2024 | — | $-0.01 | — | — |
Q3 2023 | Sep 13, 2023 | — | $-0.02 | — | — |
Q3 2023 | Aug 21, 2023 | — | $-0.02 | — | — |
Q2 2023 | Apr 10, 2023 | — | $-0.02 | — | — |
Q1 2023 | Jan 9, 2023 | — | $-0.03 | — | — |
Q4 2022 | Oct 11, 2022 | — | $-0.03 | — | — |
Q3 2022 | Aug 15, 2022 | $-0.04 | $-0.15 | -284.8% | ✗ MISS |
Q2 2022 | Apr 11, 2022 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Q1 2022 | Jan 10, 2022 | $-0.04 | $-0.06 | -43.5% | ✗ MISS |
Q4 2021 | Oct 12, 2021 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2021 | Jul 30, 2021 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about CYDY
What is CYDY's current stock price?
CytoDyn Inc. (CYDY) is currently trading at $0.28 per share. The stock has moved -1.71% today.
What is the analyst price target for CYDY?
No analyst price targets are currently available for this stock.
What sector is CytoDyn Inc. in?
CytoDyn Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is CYDY's market cap?
CytoDyn Inc. has a market capitalization of $0.35 billion, making it a small-cap company.
Does CYDY pay dividends?
No, CytoDyn Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOVNF
BioInvent International AB (publ)
$3.29
Mkt Cap: $0.2B
CLVLF
Clinuvel Pharmaceuticals Limited
$7.70
Mkt Cap: $0.4B
CLVLY
Clinuvel Pharmaceuticals Limited
$8.38
Mkt Cap: $0.4B
CMVLF
Cellectis S.A.
$4.50
Mkt Cap: $0.3B
FGHQF
Frontage Holdings Corporation
$0.15
Mkt Cap: $0.3B
HLOSF
Healios K.K.
$2.31
Mkt Cap: $0.2B
HNSBF
Hansa Biopharma AB (publ)
$2.91
Mkt Cap: $0.2B
NWBO
Northwest Biotherapeutics, Inc.
$0.25
Mkt Cap: $0.4B
PRRUF
Immutep Limited
$0.27
Mkt Cap: $0.4B
TRGNF
Transgene S.A.
$1.00
Mkt Cap: $0.1B
Explore stocks similar to CYDY for comparison